Corneal collagen crosslinking
SCHWIND eye-tech-solutions says the company is the first and only manufacturer of excimer laser systems to offer the integrated SCHWIND CXL-365 vario system for corneal collagen crosslinking (CXL). 'CXL using ultraviolet A (UVA) light and riboflavin (vitamin B2) was introduced as a clinical application to stabilise the cornea by inducing crosslinks within and between collagen fibres. CXL has been investigated extensively and has been shown clinically not only to arrest the progression of keratoconic or post-LASIK ectasia but also to exert a moderately positive effect on visual status,' said a company spokeswoman.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.